

The background features several overlapping, rounded, organic shapes in a gradient of orange and yellow. These shapes are semi-transparent and layered, creating a sense of depth and movement. The largest shape is a central orange circle that overlaps with other shapes above and below it.

# GSK Product development pipeline

February 2014



# Product development pipeline

February 2014

Option-based alliances with third parties that include assets in Phase I and Phase II development:

Company	Disease Area	Phase
Cancer Research UK	cancer	I
Dynavax Technologies	cutaneous & systemic lupus erythematosus	II
ISIS Pharmaceuticals	transthyretin-mediated amyloidosis	II/III
	hepatitis B	I
OncoMed Pharmaceuticals	oncology	I/II*
Shionogi	bacterial infection	I

\* Two assets

This document outlines GlaxoSmithKline's drug development portfolio. The content of the drug development portfolio will change over time as new compounds progress from discovery to development and from development to the market. Owing to the nature of the drug development process, many of these compounds, especially those in early stages of investigation, may be terminated as they progress through development. For competitive reasons, new projects in pre-clinical development have not been disclosed and some project types may not have been identified.

#### Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2013.



Head Office and Registered Office  
GlaxoSmithKline plc  
980 Great West Road  
Brentford, Middlesex TW8 9GS  
United Kingdom  
Tel: +44 (0)20 8047 5000  
Registered number: 3888792

[www.gsk.com](http://www.gsk.com)